• Mashup Score: 7

    We present a case of pseudo acute kidney injury (AKI) following capmatinib therapy in an 84-year-old male with combined non-small cell (adenocarcinoma) and small cell lung cancer with MET Exon 14 skipping mutation. His past medical history was significant for chronic kidney disease (CKD) stage 3 with a baseline serum creatinine (SCr) of 1.6 mg/dl rising to 2.44 mg/dL [estimated glomerular…

    Tweet Tweets with this article
    • Creatinine elevation during MET-TKI is not uncommon A nice case report describing #capmatinib induced pseudo–AKI from @MayoClinic Using cystatin C and renal iothalamate clearance, they show there was not much variation in GFR despite fluctuating Cr. https://t.co/hzHbxvg93B

  • Mashup Score: 0

    As you were browsing www.clinicaloncology.com something about your browser made us think you were a bot. There are a few reasons this might happen: You’re a power user moving through this website with super-human speed. You’ve disabled JavaScript in your web browser. A third-party browser plugin, such…

    Tweet Tweets with this article
    • .@US_FDA approves #Tabrecta @NovartisCancer to treat adults with metastatic non-small cell lung cancer. https://t.co/xE2zHXgCJu #fda #fdaapproval #lungcancer #oncology #capmatinib

  • Mashup Score: 0

    The FDA granted accelerated approval to capmatinib for treatment of certain patients with metastatic non-small cell lung cancer.The approval applies to use of capmatinib (Tabrecta, Novartis) — an oral kinase inhibitor that targets MET — for adults whose tumors have a mutation that leads to MET exon 14 skipping as detected by an FDA-approved test. The agent can be used as first-line

    Tweet Tweets with this article
    • .@US_FDA approves Tabrecta and companion diagnostic for certain patients with metastatic non-small cell lung cancer https://t.co/ieYLimFSiw @Novartis @NovartisCancer @FoundationATCG #capmatinib #NSCLC https://t.co/jhic0JraBf